我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去）

Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
6 G+ ~+ A% ^! [4 B( INOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
- l( _1 t0 \# Y( y- V( `) J( ~8 n9 B+ Author Affiliations

1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
6 L: B. m5 h) ^9 {7 D" U2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
& W. M3 E0 e9 a8 `4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
& V* S4 Y- ^# z% a$ c5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
7Kinki University School of Medicine, Osaka 589-8511, Japan
8Izumi Municipal Hospital, Osaka 594-0071, Japan
) N$ a/ M% c- m+ s$ A9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
0 }4 h7 a- }0 _) s9 g8 LCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
* x0 M/ n: J9 qAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
1 L+ ]6 }6 j8 E
  Y! m) c3 w# E! |

S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type

Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato

8 g3 R. u6 z* {) ]5 lAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
  `. N' {; W+ a) b! ]  }
Published online on: Thursday, December 1, 2011
6 U7 |6 X- ^! G
Doi: 10.3892/ol.2011.507
$ x3 d: y$ ~5 O/ S
' u- d; G1 o1 x1 ~4 U- \Pages: 405-410

Abstract:
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
% @& V- n. g0 V' Y( j

Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
$ G( Z, r9 [3 c  g9 nF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
' g% {, D! ^8 k7 U; i: z$ k9 Y) q8 S+ Author Affiliations
, M; t& e8 x; C# S1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
! e- e  k, W2 ^8 z1 Y/ G: ?7 d2Department of Thoracic Surgery, Kyoto University, Kyoto
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
, @: r9 p$ ~4 H/ d4 ?4 p) N, u2 U&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
) c% l( X1 h' O7 T) yReceived September 3, 2010.
Revision received November 11, 2010.
Accepted November 17, 2010.
$ n; j) m, ]5 [  |  hAbstract
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
$ T& w! @0 {% M7 q$ V1 f# K; W6 \  xResults: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
8 E. s3 r6 U  o9 @# aConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.

一直关注老马的帖子，前方的指明灯。祝福你爸好疗效

一直得到老马帮助，祝福老马爸爸

26日吃了12片地米（0.75mg一片），27日吃了22片地米（0.75mg 一片），28日吃了12片地米（0.75mg一片），都分二次吃。
2 i! d0 K% G' S. R0 f+ G今天为止没有任何反应，每天吃VC,VB2，还有漱口水，就怕口腔溃疡。

副作用如何，单药反应很小吧？
( H: b8 j  X) K. o. U# P9 U  m

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
http://clinicaltrials.gov/ct2/show/NCT01523587

8 Q/ h2 o: f9 y7 p  zBIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
# _: Q5 b- X/ f# thttp://clinicaltrials.gov/ct2/show/NCT01156545

从4月24日开始到4月28日，打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
$ I! k; `4 N4 T' w. G" f至今为止，未出现化疗副作用。

老马 发表于 2012-4-29 20:53

7 p0 ]7 _  \5 E, A1 o6 \. q: B                               
登录/注册后可看大图

, h% d6 h1 X" I7 h6 L. W5 L# I) m从4月24日开始到4月28日，打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
至今为止，未出 ...

: z4 R5 n7 y1 y* c1 P3 {+ j1 T1 b没有副作用是第一追求，效果显著是第二追求。
% \9 T* R9 s$ r: E) o; f/ j不错。